




Instance: composition-en-a0d64103b1c8a608be4329399bf17c80
InstanceOf: CompositionUvEpi
Title: "Composition for hyftor Package Leaflet"
Description:  "Composition for hyftor Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpabde6760299c30f30b1e966448aa9a47)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - hyftor"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Hyftor is and what it is used for  </li>
<li>What you need to know before you use Hyftor  </li>
<li>How to use Hyftor </li>
<li>Possible side effects  </li>
<li>How to store Hyftor  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What hyftor is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What hyftor is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hyftor contains the active substance sirolimus, which is a medicine that reduces the activity of the 
immune system.<br />
In patients with tuberous sclerosis complex a protein that regulates the immune system, m-TOR, is 
overactive. By blocking the activity of m-TOR, Hyftor regulates cell growth and reduces the number 
or size of angiofibromas. </p>
<p>Hyftor is a medicine used to treat adults and children from 6 years of age with angiofibroma on the 
face resulting from tuberous sclerosis complex. Tuberous sclerosis complex is a rare genetic disease 
causing non-cancerous tumours to grow in different organs of the body, including the brain and skin. 
The disease causes facial angiofibromas, non-cancerous lesions (growths) of the skin and mucous 
membranes (moist body surfaces, such as the lining of the mouth) in the face, in many patients.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take hyftor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take hyftor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Hyftor if you are allergic to sirolimus or any of the other ingredients of this medicine 
(listed in section 6) </p>
<p>Warnings and precautions<br />
Talk to your doctor before using Hyftor if you have: 
* a weakened immune system 
* severely reduced liver function </p>
<p>Avoid contact of Hyftor with the eyes, the lining of the mouth and nose, or wounds. Similarly, it 
should not be used on irritated skin or skin that is infected or otherwise damaged. 
In case of accidental contact it is recommended to immediately wash the gel off. </p>
<p>Avoid exposing skin treated with Hyftor to direct sunlight since it may cause side effects on the skin. 
This includes both natural and artificial (for example in the solarium) sunlight. Your doctor will advise 
you about appropriate sun protection, like the use of sunscreen and clothing to cover the skin or 
wearing headgear. 
Children 
Hyftor is not recommended for children under 6 years since the product has not been sufficiently 
studied in this age group.  </p>
<p>Other medicines and Hyftor 
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. </p>
<p>Do not apply other medicines to the area of skin treated with Hyftor. </p>
<p>Pregnancy and breast-feeding 
Hyftor is not recommended during pregnancy unless your doctor thinks that the benefits of treatment 
are greater than the risks. There is no information on the use of Hyftor in pregnant women. 
Women of childbearing potential should use safe contraception during treatment with Hyftor. </p>
<p>It is not known, whether sirolimus is excreted into human milk after treatment with Hyftor. You and 
your doctor should made a decision whether to discontinue breast-feeding or to discontinue/abstain 
from Hyftor therapy taking into account the benefit of breast feeding for your child and the benefit of 
therapy for you. </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask 
your doctor or pharmacist for advice before using this medicine. </p>
<p>Driving and using machines 
This medicine is not expected to affect the ability to drive or use machines. </p>
<p>Hyftor contains alcohol 
This medicine contains 458 mg alcohol (ethanol) in each gram. It may cause a burning sensation when 
applied to damaged skin. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take hyftor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take hyftor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is 
Your doctor or pharmacist will show you how much gel you should use. </p>
<p>About 0.5 cm of the gel strand twice daily is recommended for a lesion of around 7 by 7 cm (50 cm2).  </p>
<p>The maximum recommended dose on the face is:<br />
<em> children 6 to 11 years: no more than 1 cm gel strand twice daily<br />
</em> adults and children from 12 years: no more than 1.25 cm gel strand twice daily </p>
<p>How to apply the gel 
Apply a thin layer of Hyftor twice daily (morning and evening) to the affected skin area and rub in 
gently. The application should be done once in the morning and once in the evening before going to 
bed. Limit the use to skin areas affected by angiofibroma. Do not cover the affected skin after 
application of Hyftor. </p>
<p>Wash your hands carefully before and immediately after using the gel to avoid any unintentional 
spread or ingestion. </p>
<p>Duration of use 
Your doctor will tell you how long you should use Hyftor for. </p>
<p>If you use more Hyftor than you should 
Hyftor is applied to the skin and absorption into the body is minimal. This makes overdose very 
unlikely. 
If you apply too much gel to a lesion, carefully wipe off the excess gel with a paper towel and throw 
away the towel. </p>
<p>If you or anybody else accidentally swallows some gel, contact your doctor immediately. </p>
<p>If you forget to use Hyftor 
If you forget to use the medicine in the morning, apply the gel as soon as you remember immediately 
before your meal in the evening of the same day. After your meal in the evening, only administer 
Hyftor at bedtime on that day. If you forget to use the medicine at bedtime, skip that dose. Do not 
apply more gel to make up for a missed dose. </p>
<p>If you stop using Hyftor 
Your doctor will tell you how long you should use Hyftor and when you can stop treatment. Do not 
stop using it without consulting your doctor. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Very common (may affect more than 1 in 10 people) 
* dry skin 
* itching skin 
* acne 
* irritation at the application site, such as reddening, burning stinging, itching, swelling and/or 
numbness  </p>
<p>Common (may affect up to 1 in 10 people) 
* bleeding at application site 
* abnormal sensation, including at the application site, such as numbness, prickling, tingling and 
itchiness 
* application site swelling 
* eczema characterised by changes that occur when skin becomes abnormally dry, red, itchy and 
cracked 
* dermal cyst (a cyst containing solid tissue or structures such as hair) 
* rash, itchy rash 
* peeling of skin 
* skin irritation 
* reddening 
* bleeding of the skin 
* dermatitis (inflammation of the skin), including contact dermatitis (inflammation of the skin 
after contact with the medicine), acneiform dermatitis (inflammation of the skin with small 
acne-like bumps), seborrhoeic dermatitis (skin condition affecting the head with scaly and red 
skin), solar dermatitis (inflammation of the skin after exposure to sunlight) 
* dry, hard and scaly skin 
* hives 
* nodules 
* boils 
* tinea versicolour (a fungal infection of the skin) 
* inflammation of the lining of the mouth 
* increased sensitivity to light 
* reddening of the eyelid 
* red eye 
* eye irritation 
* conjunctivitis (redness and discomfort in the eye) 
* inflammation of hair follicles 
* sensations like numbness, tingling and pins and needles 
* nasal discomfort </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store hyftor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store hyftor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on the tube after EXP. 
The expiry date refers to the last day of that month. 
Store in a refrigerator (2 C   8 C). 
Store in the original tube in order to protect from light. 
Keep away from fire. </p>
<p>Throw away the tube and any remaining gel 4 weeks after opening. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Hyftor contains<br />
<em> The active substance is sirolimus. Each gram of gel contains 2 mg of sirolimus<br />
</em> The other ingredients are carbomer, anhydrous ethanol, trolamine and purified water (see 
section 2  Hyftor contains alcohol ). </p>
<p>What Hyftor looks like and contents of the pack 
Hyftor is a transparent, colourless gel. It is supplied in an aluminium tube containing 10 g of gel. </p>
<p>Pack size: 1 tube </p>
<p>Marketing Authorisation Holder 
Plusultra pharma GmbH 
Fritz-Vomfelde-Str. 40547 D sseldorf 
Germany </p>
<p>Manufacturer 
MSK Pharmalogistic GmbH.<br />
Donnersbergstra e 4<br />
64646 Heppenheim<br />
Germany </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments. </p>         </div>"""      



Instance: composition-da-a0d64103b1c8a608be4329399bf17c80
InstanceOf: CompositionUvEpi
Title: "Composition for hyftor Package Leaflet"
Description:  "Composition for hyftor Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpabde6760299c30f30b1e966448aa9a47)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - hyftor"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du bruge Hyftor 
3. Sådan skal du bruge Hyftor 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What hyftor is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What hyftor is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hyftor indeholder det aktive stof sirolimus, som er et lægemiddel, der nedsætter aktiviteten af 
immunsystemet. 
Hos patienter med tuberøs sklerosekompleks er et protein, der regulerer immunsystemet, m-TOR, 
overaktivt. Ved at blokere aktiviteten af m-TOR regulerer Hyftor cellevæksten og reducerer antallet 
eller størrelsen af angiofibromer. </p>
<p>Hyftor er et lægemiddel, der anvendes til behandling af voksne og børn fra 6 år med angiofibrom i 
ansigtet som følge af tuberøs sklerosekompleks. Tuberøs sklerosekompleks er en sjælden genetisk 
sygdom, der får svulster uden kræft til at vokse i forskellige organer i kroppen, herunder hjernen og 
huden. Sygdommen forårsager faciale angiofibromer, læsioner (vækst) uden kræft i huden og 
slimhinderne (fugtige kropsoverflader, såsom mundslimhinden) i ansigtet hos mange patienter. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take hyftor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take hyftor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Hyftor, hvis du er allergisk over for sirolimus eller et af de øvrige indholdsstoffer i Hyftor 
(angivet i punkt 6) </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du bruger Hyftor, hvis du har: </p>
<ul>
<li>
<p>et svækket immunsystem </p>
</li>
<li>
<p>svært nedsat leverfunktion </p>
</li>
</ul>
<p>Undgå, at Hyftor får kontakte med øjnene, slimhinden i mund og næse, eller sår. Det må heller ikke 
anvendes på irriteret hud eller hud, der er inficeret eller på anden måde beskadiget. 
I tilfælde af kontakt ved et uheld anbefales det straks at vaske gelen af. </p>
<p>Undgå at udsætte hud behandlet med Hyftor for direkte sollys, da det kan forårsage bivirkninger på 
huden. Dette omfatter både naturlig og kunstig sol (f.eks. solarium). Lægen vil rådgive dig om 
passende solbeskyttelse, som brugen af solfaktor og tøj til at dække huden eller hovedbeklædning. </p>
<p>Børn 
Hyftor bør ikke gives til børn under 6 år, da præparatet ikke er blevet tilstrækkeligt undersøgt til denne 
aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med Hyftor 
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger andre lægemidler, for nylig har brugt 
andre lægemidler eller planlægger at bruge andre lægemidler. </p>
<p>Påfør ikke andre lægemidler til det hudområde, der bliver behandlet med Hyftor. </p>
<p>Graviditet og amning 
Hyftor bør ikke anvendes under graviditeten, medmindre din læge mener, at fordelen ved 
behandlingen opvejer risici. Der er ingen information om anvendelsen af Hyftor til gravide kvinder. 
Kvinder i den fertile alder skal anvende sikker prævention under behandlingen med Hyftor. </p>
<p>Det er ukendt, om sirolimus udskilles i human mælk efter behandling med Hyftor. Du skal sammen 
med lægen beslutte, om amning eller behandling med Hyftor skal ophøre, idet der tages højde for 
fordelene ved amning for barnet i forhold til de terapeutiske fordele for dig. </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du bruger dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Dette lægemiddel forventes ikke at påvirke din evne til at føre køretøj eller betjene maskiner. </p>
<p>Hyftor indeholder alkohol 
Dette lægemiddel indeholder 458 mg alkohol (ethanol) pr. gram. Det kan forårsage en brændende 
fornemmelse på skadet hud. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take hyftor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take hyftor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er 
Din læge eller apotekspersonalet vil fortælle dig, hvor meget gel du skal bruge. </p>
<p>Ca. 0,5 cm gelstreng to gange dagligt anbefales for en læsion på omkring 7 gange 7 cm (50 cm2). </p>
<p>Den maksimale anbefalede dosis i ansigtet er: </p>
<ul>
<li>
<p>børn i alderen 6 til 11 år: ikke over 1 cm gelstreng to gange dagligt </p>
</li>
<li>
<p>voksne og børn fra 12 år: ikke over 1,25 cm gelstreng to gange dagligt </p>
</li>
</ul>
<p>Sådan påføres gelen 
Et tyndt lag Hyftor påføres to gange dagligt (morgen og aften) til det berørte hudområde og gnid 
forsigtigt ind. Gelen skal påføres én gang om morgenen og én gang om aftenen inden sengetid. 
Begræns brugen af gelen til hudområder berørt af angiofibrom. Det berørte hudområde må ikke 
tildækkes efter applikation af Hyftor. </p>
<p>Vask hænderne grundigt inden og umiddelbart efter du bruger gelen, for at undgå utilsigtet spredning 
og indtagelse. </p>
<p>Behandlingsvarighed 
Din læge vil fortælle dig, hvor længe du skal bruge Hyftor. </p>
<p>Hvis du har brugt for meget Hyftor 
Hyftor påføres på huden og absorptionen i kroppen er minimal. Det gør en overdosering meget 
usandsynlig. 
Hvis du påfører for meget gel på en læsion, skal du forsigtigt tørre overskydende gel af med en 
papirserviet og smide den væk. </p>
<p>Hvis du eller andre ved et uheld sluger noget gel, skal du straks kontakte din læge. </p>
<p>Hvis du har glemt at bruge Hyftor 
Hvis du har glemt at bruge lægemidlet om morgenen, kan du stadig påføre gelen så snart du husker på 
det, umiddelbart før dit aftensmåltid samme dag. Efter dit aftensmåltid må du kun administrere Hyftor 
ved sengetid den dag. Hvis du har glemt at bruge lægemidlet ved sengetid, skal du springe den dosis 
over. Du må ikke påføre mere gel som erstatning for en glemt dosis. </p>
<p>Hvis du holder op med at bruge Hyftor 
Din læge vil fortælle dig, hvor længe du skal bruge Hyftor, og hvornår du kan holde op med 
behandlingen. Du må ikke holde op med at bruge det uden at kontakte din læge. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer) </p>
<ul>
<li>
<p>tør hud </p>
</li>
<li>
<p>kløende hud </p>
</li>
<li>
<p>akne </p>
</li>
<li>
<p>irritation på applikationsstedet, såsom rødme, brændende eller stikkende fornemmelse, kløe, 
hævelse og/eller følelsesløshed </p>
</li>
</ul>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>blødning på applikationsstedet </p>
</li>
<li>
<p>unormal fornemmelse, herunder på applikationsstedet, såsom følelsesløshed, sovende 
fornemmelse, prikken, stikken og kløe </p>
</li>
<li>
<p>hævelse på applikationsstedet </p>
</li>
<li>
<p>eksem karakteriseret ved ændringer, der opstår, når huden bliver unormalt tør, rød, kløende og 
revnet </p>
</li>
<li>
<p>dermal cyste (en cyste, der indeholder fast væv eller strukturer, såsom hår) </p>
</li>
<li>
<p>udslæt, kløende udslæt </p>
</li>
<li>
<p>hudafskalning </p>
</li>
<li>
<p>hudirritation </p>
</li>
<li>
<p>rødme </p>
</li>
<li>
<p>hudblødning </p>
</li>
<li>
<p>dermatitis (betændelse i huden), herunder kontaktdermatitis (betændelse i huden efter kontakt 
med lægemidlet), acneiform dermatitis (betændelse i huden med små akne-lignende knopper), 
seboroisk dermatitis (hudtilstand, der påvirker hovedet med skællende og rød hud), 
soldermatitis (betændelse i huden efter udsættelse for sollys) </p>
</li>
<li>
<p>tør, hård og skællende hud </p>
</li>
<li>
<p>nældefeber </p>
</li>
<li>
<p>knuder </p>
</li>
<li>
<p>bylder </p>
</li>
<li>
<p>tinea versicolour (en svampeinfektion i huden) </p>
</li>
<li>
<p>betændelse i mundens slimhinde </p>
</li>
<li>
<p>øget lysfølsomhed </p>
</li>
<li>
<p>rødme af øjenlåg </p>
</li>
<li>
<p>røde øjne </p>
</li>
<li>
<p>øjenirritation </p>
</li>
<li>
<p>øjenbetændelse (rødme og ubehag i øjet) </p>
</li>
<li>
<p>betændelse af hårfollikler </p>
</li>
<li>
<p>fornemmelser som følelsesløshed, sovende fornemmelse og prikken og stikken </p>
</li>
<li>
<p>næseubehag </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store hyftor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store hyftor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og tuben efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned. 
Opbevares i køleskab (2 °C - 8 °C). 
Opbevares i den originale tube for at beskytte mod lys. 
Holdes væk fra åben ild. </p>
<p>Bortskaf tuben og al resterende gel 4 uger efter anbrud. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hyftor indeholder: </p>
<ul>
<li>
<p>Aktivt stof: sirolimus. Hver gram gel indeholder 2 mg sirolimus </p>
</li>
<li>
<p>Øvrige indholdsstoffer: Carbomer, ethanol, vandfrit, trolamin og renset vand (se pkt. 2 "Hyftor 
indeholder alkohol"). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Hyftor er en gennemsigtig, farveløs gel. Den leveres i en aluminiumstube indeholdende10 g gel. </p>
<p>Pakningsstørrelse: 1 tube </p>
<p>Indehaver af markedsføringstilladelsen 
Plusultra pharma GmbH 
Fritz-Vomfelde-Str. 40547 Düsseldorf 
Tyskland </p>
<p>Fremstiller 
MSK Pharmalogistic GmbH 
Donnersbergstraße 4 
64646 Heppenheim 
Tyskland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>-
Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-a0d64103b1c8a608be4329399bf17c80
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for hyftor Package Leaflet for language en"
Description: "ePI document Bundle for hyftor Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-a0d64103b1c8a608be4329399bf17c80"
* entry[0].resource = composition-en-a0d64103b1c8a608be4329399bf17c80

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa0d64103b1c8a608be4329399bf17c80"
* entry[=].resource = mpa0d64103b1c8a608be4329399bf17c80
                            
                    
Instance: bundlepackageleaflet-da-a0d64103b1c8a608be4329399bf17c80
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for hyftor Package Leaflet for language da"
Description: "ePI document Bundle for hyftor Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-a0d64103b1c8a608be4329399bf17c80"
* entry[0].resource = composition-da-a0d64103b1c8a608be4329399bf17c80

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa0d64103b1c8a608be4329399bf17c80"
* entry[=].resource = mpa0d64103b1c8a608be4329399bf17c80
                            
                    



Instance: mpa0d64103b1c8a608be4329399bf17c80
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product hyftor"
Description: "hyftor"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/23/1723/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "hyftor"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: a0d64103b1c8a608be4329399bf17c80ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "hyftor"

* status = #current
* mode = #working

* title = "List of all ePIs associated with hyftor"

* subject = Reference(mpabde6760299c30f30b1e966448aa9a47)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#hyftor "hyftor"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-a0d64103b1c8a608be4329399bf17c80) // hyftor en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-a0d64103b1c8a608be4329399bf17c80) // hyftor da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-a0d64103b1c8a608be4329399bf17c80
InstanceOf: List

* insert a0d64103b1c8a608be4329399bf17c80ListRuleset
    